Evidence to date: talazoparib in the treatment of breast cancer
Approximately 5-10% of all patients diagnosed with breast cancer have germline mutations, which make their disease more susceptible to DNA-damaging agents and a new class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors. Talazoparib is a new PARP inhibitor that has been recently appro...
Saved in:
Published in | OncoTargets and therapy Vol. 12; pp. 5177 - 5187 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
New Zealand
Dove Medical Press Limited
01.07.2019
Dove Dove Medical Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Approximately 5-10% of all patients diagnosed with breast cancer have germline
mutations, which make their disease more susceptible to DNA-damaging agents and a new class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors. Talazoparib is a new PARP inhibitor that has been recently approved for use in patients with metastatic breast cancer with germline
mutations after a phase III trial showed superior progression-free survival when compared to standard chemotherapy. In this review, we analyze the development of talazoparib as well as its safety profile and the potential role of the combination therapy with standard cytotoxic drugs and with novel therapies. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 1178-6930 1178-6930 |
DOI: | 10.2147/OTT.S184971 |